Sangamo Therapeutics, Inc.

NasdaqCM:SGMO Stok Raporu

Piyasa değeri: US$391.5m

Sangamo Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Sangamo Therapeutics' CEO is Sandy Macrae, appointed in Jun 2016, has a tenure of 8.42 years. total yearly compensation is $2.39M, comprised of 29.9% salary and 70.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $744.90K. The average tenure of the management team and the board of directors is 2.4 years and 5 years respectively.

Anahtar bilgiler

Sandy Macrae

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi29.9%
CEO görev süresi8.4yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi2.4yrs
Yönetim Kurulu ortalama görev süresi5yrs

Son yönetim güncellemeleri

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

Recent updates

What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Oct 23
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?

Oct 21

There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump

Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking

Jul 23

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop

We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package

This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year

Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding

Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%

We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Mar 09
We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate

Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Feb 02
Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet

Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Dec 04
Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Sep 11
Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Aug 15
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Aug 08
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S

Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

May 30
Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be

Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

May 13
Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)

Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

Apr 11
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky

We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Dec 20
We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully

Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy

Sep 22

Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sep 18
Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation

Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead

Aug 31

Sangamo Therapeutics: Cheap, But Justifiably So

Aug 09

Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

May 08
Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates

Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Apr 11
Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?

Sangamo Therapeutics: Lost In Transition From Lab To Clinic

Feb 24

Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Jan 10
Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

Dec 03

CEO Tazminat Analizi

Sandy Macrae'un ücretlendirmesi Sangamo Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$250m

Mar 31 2024n/an/a

-US$328m

Dec 31 2023US$2mUS$716k

-US$258m

Sep 30 2023n/an/a

-US$250m

Jun 30 2023n/an/a

-US$199m

Mar 31 2023n/an/a

-US$127m

Dec 31 2022US$5mUS$709k

-US$192m

Sep 30 2022n/an/a

-US$178m

Jun 30 2022n/an/a

-US$172m

Mar 31 2022n/an/a

-US$176m

Dec 31 2021US$5mUS$689k

-US$178m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$124m

Dec 31 2020US$4mUS$682k

-US$121m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$102m

Mar 31 2020n/an/a

-US$96m

Dec 31 2019US$4mUS$662k

-US$95m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$104m

Mar 31 2019n/an/a

-US$90m

Dec 31 2018US$4mUS$636k

-US$68m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$58m

Dec 31 2017US$2mUS$612k

-US$55m

Tazminat ve Piyasa: Sandy's total compensation ($USD2.39M) is about average for companies of similar size in the US market ($USD2.41M).

Tazminat ve Kazançlar: Sandy's compensation has been consistent with company performance over the past year.


CEO

Sandy Macrae (61 yo)

8.4yrs

Görev süresi

US$2,392,272

Tazminat

Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Alexander Macrae
CEO, President & Director8.4yrsUS$2.39m0.19%
$ 744.9k
Prathyusha Duraibabu
Senior VP5.4yrsUS$1.06m0.036%
$ 140.3k
Nathalie Dubois-Stringfellow
Senior VP & Chief Development Officer5.8yrsUS$1.03m0.044%
$ 170.8k
Amy Pooler
Head of Researchless than a yearVeri yok0.014%
$ 54.5k
Gregory Davis
Head of Technologyless than a yearVeri yok0.018%
$ 71.7k
Aron Feingold
Head of Corporate Communications & Investor Relations Officerno dataVeri yokVeri yok
Scott Willoughby
Senior VP3.3yrsVeri yok0.041%
$ 161.2k
Phillip Ramsey
Head of Technical Operations1.5yrsVeri yokVeri yok
Stephanie J. Seiler
Head of Business Development & Alliance Managementless than a yearVeri yokVeri yok
David Ojala
Scientist II - Discovery & Translational Researchno dataVeri yokVeri yok
Louise Wilkie
Vice President of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok

2.4yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: SGMO's management team is considered experienced (2.4 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Alexander Macrae
CEO, President & Director8.4yrsUS$2.39m0.19%
$ 744.9k
H. Parker
Independent Chairwoman of the Board10.4yrsUS$99.28k0.030%
$ 117.7k
Robert Carey
Independent Director8.4yrsUS$80.53k0.024%
$ 93.2k
Stuart Schreiber
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Robert Desnick
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Roger Kornberg
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Samuel A. J. Aparicio
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Jef Boeke
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Karen Smith
Independent Director6.4yrsUS$76.78k0.025%
$ 97.9k
Megan Levings
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Michael Grunstein
Member of Scientific Advisory Board5yrsVeri yokVeri yok
Douglas Higgs
Member of Scientific Advisory Board5yrsVeri yokVeri yok

5.0yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SGMO's board of directors are considered experienced (5 years average tenure).